Cargando…
Pharmaceutical company perspectives on current safety risk communications in Japan
In 1987, a group infection of hepatitis in patients receiving a contaminated fibrinogen product was first reported to the Japanese regulatory agency. Eventually, this serious drug incident involved more than 10,000 cases of infection. In response, the Government of Japan established a responding ins...
Autores principales: | Urushihara, Hisashi, Kobashi, Gen, Masuda, Hideaki, Taneichi, Setsuko, Yamamoto, Michiko, Nakayama, Takeo, Kawakami, Koji, Matsuda, Tsutomu, Ohta, Kaori, Sugimori, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921345/ https://www.ncbi.nlm.nih.gov/pubmed/24555168 http://dx.doi.org/10.1186/2193-1801-3-51 |
Ejemplares similares
-
Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019) -
Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan
por: Maeda, Hideki
Publicado: (2021) -
Adaptation of the European Commission-recommended user testing method to patient medication information leaflets in Japan
por: Yamamoto, Michiko, et al.
Publicado: (2017) -
Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010
por: Nakaoka, Sachiko, et al.
Publicado: (2014) -
Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)